#United States #College Station #University Health Network #Matica Biotechnology #IL-10 Therapy

Matica Biotechnology Partners with UHN for Lung Transplant Therapy

In a significant advancement in transplant medicine, Matica Biotechnology, Inc. has established a collaboration with University Health Network (UHN) to provide cGMP manufacturing services for an innovative treatment method. The focus of this partnership is the development of IL-10 adenoviral gene therapy, which is particularly designed for use during the ex vivo lung perfusion (EVLP) process prior to lung transplantation.

An Exciting Partnership

On June 9, 2026, Matica Bio, a prominent contract development and manufacturing organization (CDMO) specializing in advanced therapies, revealed the details of its engagement with UHN. Under this agreement, Matica will be responsible for a comprehensive suite of development and manufacturing services. These include the generation of research cell banks, synthesis and amplification of adenovirus seeds, process and analytical development, and ultimately, the cGMP manufacturing of the adenoviral vector.

According to Paul Kim, CEO of Matica Bio, the company is honored to partner with the Toronto General Hospital to enhance outcomes in lung transplantation. He emphasized that their team's expertise in adenoviral vector process development and manufacturing will play a crucial role in advancing this promising therapy towards clinical development.

The Role of EVLP in Transplant Medicine

The EVLP technique represents a groundbreaking innovation in the field of transplantation. This method allows for the assessment and rehabilitation of donor lungs outside the body, providing a critical window for medical professionals to evaluate the viability of these organs prior to their transplantation into patients. By integrating gene therapy approaches, such as the administration of IL-10, researchers aim to address inflammation and improve graft function, potentially making more lung transplants available and increasing their success rates.

A Trusted Partner in Advanced Therapies

This collaboration underscores Matica Bio’s expanding role as a reliable CDMO partner for viral vector programs spanning gene therapy, immuno-oncology, and regenerative medicine. The company offers complete development and manufacturing solutions, from initial process development to cGMP production, ensuring a seamless journey from concept to execution.

About Matica Biotechnology

Matica Biotechnology is a trailblazer in the realm of viral vector CDMO services. The organization harnesses state-of-the-art technologies within its specially designed cGMP facilities. With unparalleled expertise in process and assay development, alongside cGMP manufacturing, Matica Bio positions itself as a trusted collaborator for clients, delivering smooth operations throughout every project phase. The company’s multi-site global collaboration ensures top-tier performance within the CDMO landscape, aided by advanced innovations such as proprietary MatiMax™ cell lines, in-line process monitoring, and single-use technologies.

To gain further insight into Matica Bio, interested parties can visit their official website at www.maticabio.com.